Holen Sie sich die Stockscreener-App
0.69
0.10%
0.0007
Schlusskurs vom Vortag:
$0.6893
Offen:
$0.7065
24-Stunden-Volumen:
72,906
Relative Volume:
0.32
Marktkapitalisierung:
$7.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.28M
KGV:
-0.6631
EPS:
-1.0406
Netto-Cashflow:
$-4.80M
1W Leistung:
-11.56%
1M Leistung:
-2.10%
6M Leistung:
-31.68%
1J Leistung:
-46.92%
1-Tages-Spanne:
$0.6789
$0.749
1-Wochen-Bereich:
$0.66
$0.819
52-Wochen-Spanne:
$0.63
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Firmenname
Pharmacyte Biotech Inc
Sektor
Branche
Telefon
(917) 595.2850
Adresse
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.90 | 2.52B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.70 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.94 | 364.47M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.35 | 297.48M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
43.81 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Aktie (PMCB) Neueste Nachrichten
Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB) - Stock Titan
Director at PharmaCyte Biotech (PMCB) gets 119,170 options - Stock Titan
PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech Shareholders Approve Governance and Equity Actions - TipRanks
PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares - Stock Titan
PMCB Stock Chart | PHARMACYTE BIOTECH INC (NASDAQ:PMCB) - ChartMill
Insider Sell: How liquid is PharmaCyte Biotech Inc stock2026 Setups & Safe Entry Momentum Tips - baoquankhu1.vn
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
PharmaCyte Biotech, Inc. (PMCB) Q3 2026 10-Q Report: Financial Results, Stock Information, and SEC Filings - Minichart
PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD) - TradingView
PharmaCyte Biotech (NASDAQ: PMCB) details Jan 2026 results and cash runway - Stock Titan
PharmaCyte Biotech delays quarterly report filing - MSN
Analyzing Prime Medicine (NYSE:PRME) & PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PharmaCyte Biotech (PMCB) seeks reverse split, equity plan boost at 2026 meeting - Stock Titan
Aug Catalysts: Can PharmaCyte Biotech Inc. stock weather global recessionWeekly Profit Summary & Safe Capital Growth Plans - Naître et grandir
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits
PMCB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Technical Analysis - Intellectia AI
PharmaCyte Biotech (PMCB) seeks reverse split and 2M share plan boost at virtual meeting - Stock Titan
Day Trade: Can PharmaCyte Biotech Inc keep up with sector leadersJuly 2025 Trends & Free Long-Term Investment Growth Plans - baoquankhu1.vn
PharmaCyte Biotech Inc. (PMCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading 5.9% Higher – Time to Buy? - Defense World
Volume Summary: What is SIM Acquisition Corp Is P E ratio telling usJuly 2025 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
Dow Update: Is PharmaCyte Biotech Inc vulnerable to short sellersMarket Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
Is PharmaCyte Biotech Inc. trading at a discountWeekly Stock Report & Weekly High Momentum Picks - mfd.ru
Is PharmaCyte Biotech Inc. vulnerable to short sellersJuly 2025 Price Swings & Fast Momentum Stock Entry Tips - bollywoodhelpline.com
Dividend Watch: Is PharmaCyte Biotech Inc in a bullish channelJuly 2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 4.3% – Time to Sell? - Defense World
Bull Run: Why PharmaCyte Biotech Inc stock attracts high net worth investorsInsider Selling & Weekly Breakout Watchlists - Bộ Nội Vụ
PharmaCyte Biotech stock surges following profitable exit from Femasys investment - MSN
Hedge Fund and Insider Trading News: Paul Singer, Steve Cohen, Israel Englander, Ray Dalio, Rokos Capital Management, Viking Global, PharmaCyte Biotech Inc (PMCB), Cloudflare Inc (NET), and More - Insider Monkey
Why PharmaCyte Biotech Inc. stock could see breakout soonJuly 2025 Retail & Daily Growth Stock Tips - Улправда
Why PharmaCyte Biotech Inc. stock appeals to analystsJuly 2025 Outlook & Technical Entry and Exit Tips - Улправда
Will PharmaCyte Biotech Inc. stock rally after Fed decisionsWeekly Stock Report & Low Drawdown Trading Strategies - ulpravda.ru
How currency fluctuations impact PharmaCyte Biotech Inc. stockEarnings Summary Report & Long-Term Safe Investment Ideas - ulpravda.ru
Will PharmaCyte Biotech Inc. stock keep outperforming rivals2025 Sector Review & Risk Controlled Stock Alerts - Улправда
Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 By Investing.com - Investing.com Nigeria
PMCB Stock Insider Trading Activity - Quiver Quantitative
Pharmacyte Biotech CEO Silverman buys $80k in shares By Investing.com - Investing.com Nigeria
Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 - Investing.com
Pharmacyte Biotech CEO Silverman buys $80k in shares - Investing.com
How institutional buying supports PharmaCyte Biotech Inc. stockEarnings Per Share Trends & Minimal Investment Trading Tips - ulpravda.ru
PharmaCyte Biotech (PMCB) Stock Analysis Report | Financials & Insights - Benzinga
Largest borrow rate increases among liquid names - TipRanks
Finanzdaten der Pharmacyte Biotech Inc-Aktie (PMCB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):